Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW
2005 ◽
Vol 43
(12)
◽
pp. 590-591
◽
Keyword(s):
Phase I
◽
2005 ◽
Vol 43
(12)
◽
pp. 566
Keyword(s):
2007 ◽
Vol 97
(11)
◽
pp. 1480-1485
◽
2004 ◽
Vol 42
(11)
◽
pp. 631
Keyword(s):